French Trial Tragedy: FDA Launches 'FAAH' Safety Probe
This article was originally published in Scrip
Executive Summary
US regulators on Jan. 22 said they are conducting a safety probe of fatty acid amide hydrolase (FAAH) inhibitors being developed and studied in the US after one healthy volunteer in a French Phase I trial testing a product in that class died and five other participants experienced severe adverse neurological events.